EMA approves marketing authorization application for Lumoxiti®
Category: #health  | By Mateen Dalal  | Date: 2020-01-03 |
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

EMA approves marketing authorization application for Lumoxiti®

Innate Pharma SA, a commercial-stage oncology-focused biotech firm, has successfully attain Marketing Authorization Application (MMA) approval for Lumoxiti from the European Medicines Agency (EMA). For the record, Lumoxiti is a first-in-class drug directed for adult patients who are suffering from refractory or relapsed hairy cell leukemia (HCL) and have received a minimum two preceding systemic therapies, including treatment with a purine nucleoside analog. 

Speaking on the approval, Pierre Dodion, MD, Executive VP & CMO, Innate Pharma, said that the drug, following its authorization by the EMA, would become first treatment available in Europe for relapsed or refractory HCL patients in over twenty years, potentially transforming the standard of care for these patients.

Dodion assured that their firm is dedicated towards addressing the unmet need for treating this rare type of cancer that could result in fatal conditions and would bring this drug to patent in Europe as soon as possible.

As per reports, the EMA filing was based on the final study of the Phase III trial of Lumoxiti, demonstrated at ASH 2019. According to the data, around 36 percent (29/80) of the relapsed or refractory HCL patients attained durable complete response (specified as a CR) with a hematological remission retained for at least 180 days.

The ORR (objective response rate) was at 75%, whereas 81% of patients with CR underwent elimination of minimal residual disease as reflected by MRD-negative status. Additionally, there was a 61% possibility that patients who attained a CR would retain it after five years.

Reportedly, the EMA filing acceptance for Lumoxiti follows the U.S. FDA (Food and Drug Administration) approval in Sept. 2018.

About Innate Pharma S.A.

It is an oncology-focused biotech organization dedicated to improving clinical and treatment results for patients through therapeutic antibodies that utilize the immune system to fight against cancer.
 

Souce Creidit – https://www.innate-pharma.com/en/news-events/press-releases/european-medicines-agency-accepts-regulatory-submission-lumoxiti-relapsed-or-refractory-hairy-cell-leukemia

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal     twitter

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More..

More News By Mateen Dalal

Hyundai Motor Company & Advent sign JDA to develop fuel cell technology

Hyundai Motor Company & Advent sign JDA to develop fuel cell technology

By Mateen Dalal

Hyundai Motor Company and Advent Technologies have entered into a joint development agreement, following the assessment of Advent’s Proprietary Membrane Electrode Assembly (MEA) technology. The evaluation was focused on the ability of Advent&rs...

Intellect chooses IHH Healthcare to devise mental health programs

Intellect chooses IHH Healthcare to devise mental health programs

By Mateen Dalal

Intellect, a leading mental health platform located in Singapore, has reportedly announced a partnership with IHH Healthcare, which is Asia’s largest private healthcare group. The main objective of the partnership is to introduce and customize ...

Dyson compensates employees with onetime payment in absence of bonus

Dyson compensates employees with onetime payment in absence of bonus

By Mateen Dalal

Dyson, a British company renowned for its innovative vacuum cleaners, hair dryers and other products, is reportedly offering a majority of the staff at its Singapore headquarters a one-time payment, in recognition of their exceptional contribution. ...